Drug Type Monoclonal antibody |
Synonyms LY 3041658, LY-3041658, LY3041658 |
Target |
Mechanism CXCR1 antagonists(C-X-C motif chemokine receptor 1 antagonists), CXCR2 antagonists(C-X-C motif chemokine receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis, Ulcerative | Phase 2 | US | 01 Sep 2024 | |
Hidradenitis Suppurativa | Phase 2 | US | 26 Aug 2020 | |
Hidradenitis Suppurativa | Phase 2 | AU | 26 Aug 2020 | |
Psoriasis | Phase 1 | US | 08 Nov 2016 |
Phase 2 | 67 | LY3041658 600 mg | nzxrskizfk(rylhcbblqf) = dsoyzrxfdh eaxpxbggit (gmhwzbjidh ) | - | 11 Oct 2023 |